In a note to investors Monday, Umer Raffat, an analyst with Evercore ISI, labeled lotigliprons discontinuation a big setback, not just on Pfizers overall GLP effort but also from a broader pipeline perspective
But if you're looking for little optimalities or ways to sweeten things up that are not sugar or not an artificial sweetener, this could be a really cool little corner case
The health benefits of metformin extend beyond diabetes
As of February 2026, about two-thirds of respondents think GLP-1 drugs are somewhat or a little risky, whereas only 6 percent think they are not at all risky
Semaglutide is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes at doses up to 2 mg weekly, not for weight loss
Month 3+: Maximum benefits usually develop, with continued improvement possible